HOME >> BIOLOGY >> NEWS
Conference to address the challenge of renewable resources

A major international conference focusing on the growing impact of Renewable Resources will take place at the University of York, in the UK, next September.

The three-day symposium, which starts on 6 September 2006, will bring together academics, industrialists and policy-makers to discuss the challenges the world faces in embracing renewable resources - and present novel developments in their use.

The event at York will build on the success of the inaugural Renewable Resources and Biorefineries Conference hosted by the University of Ghent in Belgium on 19-21 September 2005, that attracted 330 delegates from 28 countries including Dr Christian Patermann, EU Director for Biotech, Agriculture and Food Research, representatives from the US Dept of Agriculture and from all levels of national governments.

As a Science City and with a University that is a centre for world-class research in Biotechnology and Green Chemistry, York is the ideal venue to host the second of these events.

Featuring a series of keynote speakers, the York conference will also include plenary lectures, oral presentations and an exhibition of scientific equipment and services.

The conference will highlight a range of topics including:

  • European Policy and Socio-Economic Issues
  • Biorefineries
  • Renewable Feedstocks for chemical manufacture
  • Industrial biotechnology and bioprocessing
  • Carbohydrates and Oleochemicals
  • New Materials and Products based on Renewable Resources
  • Biofuels and Bio-energy
  • Sustainability of the use of renewable resources
  • Investment

    Professor James Clark, of the York event's organising committee, said: "The inaugural conference in Ghent was inspirational and we want to build on its tremendous success."

    Details of how to reserve places at the symposium will be announced early in the New Year.


    '"/>



  • Contact: David Garner
    dcg501@york.ac.uk
    44-190-443-2153
    University of York
    19-Dec-2005


    Page: 1

    Related biology news :

    1. National Ecological Observatory Network featured at ESA/SER Joint International Conference
    2. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
    3. Naval Science and Technology Conference 2007
    4. Scientists to make news at Computational Biology Conference
    5. NY Stem Cell Foundations 2nd Annual Translational Stem Cell Research Conference
    6. Journalists can register now for ECCO 14 -- the European Cancer Conference
    7. Global community listens to TAU genetic researcher at EU Conference on Hearing Loss
    8. Conference to examine role technology can play in managing health care costs
    9. Energy 2100 Conference rescheduled to Fall 2007
    10. ANA 2007 Quadrennial Policy Conference
    11. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: Conference address the challenge renewable resources

    (Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
    (Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
    (Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
    Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
    (Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
    (Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
    (Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
    (Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
    Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
    Cached News: